If you have been reading about research chemical and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-18. Numbers and descriptions here follow the published literature rather than marketing material.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
==== Promethazine ==== Promethazine is one of the recommended drugs by NASA to treat space motion sickness and studies have been conducted to analyze their pharmacological responses in outer space. Studies on promethazine were performed exclusively on Earth, called earthbound models, stimulating microgravity and weightlessness through forty-eight hours of bed rest. The −6° head-down best rest model, where individuals are placed lying 6 degrees down to study weightlessness. This type of model simulates the shift in fluid from the bottom to the top of the body, as well as bone loss, found in astronauts in weightless environments. Using twelve volunteers, 50 mg of promethazine was delivered orally or intramuscularly to the deltoid muscle before and after forty-eight hours of bedrest. Blood was examined at intervals of 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-drug deliverance and promethazine levels were detected using plasma promethazine assays, which uses liquid chromatography to quantify promethazine kinetics. The study determined that higher concentrations of promethazine were found in the blood through oral delivery and bioavailability factors was impacted through weightlessness.
=== Before the search === The earliest mention of some matter with the properties of deuterium was a passing mention in Ernest Rutherford's 1919 Bakerian lecture. In this theory, the deuterium nucleus with mass two and charge one would contain two protons and one nuclear electron. Also in 1919, Otto Stern and Max Volmer reported on diffusion experiments with water which they claimed disproved the existence of isotopes of hydrogen; their conclusions were assumed to be correct throughout the 1920s.
Every patient has their own body condition, for example, kidney function, liver function, genetic variations, medical history, etc. These are all the factors that should be considered by healthcare professionals before giving any pharmacological therapy. Most importantly, the advancing technology in genetics guides us to have more insight into the linkage between health and genes. In pharmacological therapy, two areas of study are evolving: pharmacogenetics and pharmacogenomics. Age will affect the pharmacokinetics and pharmacodynamics of drugs, and hence the efficacy of the therapy. The effect of age causes deterioration of organ function, like liver function and kidney function. Pharmacokinetics is the study of drugs' effects on absorption, distribution, metabolism, and elimination. Pharmacodynamics is the study of drugs' effects on our body and their mechanisms.
Less common but occasional symptoms include erythrocytosis, leukocytosis, and proteinuria. The physical changes of hypersomatotropism are a result of anabolic effects of growth hormone and IGF-1; these have a gradual onset and progress slowly. The overgrowth of soft tissue and bone changes cause weight gain, broadening of the skull, prognathia inferior, and an enlarged tongue. Thickening of the oropharyngeal tissue may lead to respiratory distress and stridor. Degenerative anthropathy is caused by proliferation of chondrocytes and changes to the joint geometry. Heart murmur occurs in most feline cases, further diagnostics may reveal cardiomegaly and other heart abnormalities. Congestive heart failure can occur during later stages of the disease. A 1990 study reported 50% of cats diagnosed with hypersomatotropism had developed renal failure within 8–36 months of initial examination; however, another study from 2007 found a 12% incidence of azotaemia. Renal failure is a very common disease in elderly cats and it is controversial as to whether or not feline hypersomatotropism affects the development of renal failure. In dogs the symptoms of diabetes mellitus commonly overshadows acromegalic symptoms.
The submucosa (tela submucosa), or submucosal layer, is a thin layer of tissue in various organs of the gastrointestinal, respiratory, and genitourinary tracts. It is the layer of dense irregular connective tissue that supports the mucosa (mucous membrane) and joins it to the muscular layer, the bulk of overlying smooth muscle (fibers running circularly within layer of longitudinal muscle). The submucosa (sub- + mucosa) is to a mucous membrane what the subserosa (sub- + serosa) is to a serous membrane.
Sources: en.wikipedia.org
The first example of a dinitrogen complex to be discovered was [Ru(NH3)5(N2)]2+ (see figure at right), and soon many other such complexes were discovered. These complexes, in which a nitrogen molecule donates at least one lone pair of electrons to a central metal cation, illustrate how N2 might bind to the metal(s) in nitrogenase and the catalyst for the Haber process: these processes involving dinitrogen activation are vitally important in biology and in the production of fertilisers. Dinitrogen is able to coordinate to metals in five different ways. The more well-characterised ways are the end-on M←N≡N (η1) and M←N≡N→M (μ, bis-η1), in which the lone pairs on the nitrogen atoms are donated to the metal cation. The less well-characterised ways involve dinitrogen donating electron pairs from the triple bond, either as a bridging ligand to two metal cations (μ, bis-η2) or to just one (η2). The fifth and unique method involves triple-coordination as a bridging ligand, donating all three electron pairs from the triple bond (μ3-N2). A few complexes feature multiple N2 ligands and some feature N2 bonded in multiple ways. Since N2 is isoelectronic with carbon monoxide (CO) and acetylene (C2H2), the bonding in dinitrogen complexes is closely allied to that in carbonyl compounds, although N2 is a weaker σ-donor and π-acceptor than CO. Theoretical studies show that σ donation is a more important factor allowing the formation of the M–N bond than π back-donation, which mostly only weakens the N–N bond, and end-on (η1) donation is more readily accomplished than side-on (η2) donation.
In March 1929, the Grand Lodge of Cuba created a youth organization called the Young Fraternal Hope Association (AJEF) (Spanish: Asociación de Jóvenes Esperanza de la Fraternidad), whose original charter was valid until February 1936. On February 9, 1936, through the efforts of its founder Fernando Suárez Núñez, AJEF established its first Lodge, Logia Esperanza. AJEF comprised young men ages 14 to 21, and in time, it spread beyond Cuba, into Mexico and South America.
== Molecular characteristics == PDRN is a polyanionic, hydrophilic molecule whose molecular weight varies due to differences in biological extraction and purification processes. Even though this molecule ranges from 50 to 1500 kDa (primarily between 80 - 200 kDa), lower-molecular-weight fragments have shown better biological activity compared to higher-molecular-weight counterparts. Salmon-derived PDRN fragment characteristics have become the standard because of its ready availability and ease of processing, yields highly purified product (~95%) helping avoid potential immunological side effects.
== Research == Flunarizine may help to reduce the severity and duration of attacks of paralysis associated with the more serious form of alternating hemiplegia, as well as being effective in rapid onset dystonia-parkinsonism (RDP). Both these conditions arise from specific mutations in the ATP1A3 gene. Flunarizine extended motor neuron survival in spinal cord, protected skeletal muscles from cell death and atrophy and extended survival by 40% in an animal model of spinal muscular atrophy. Flunarizine has also shown promise as an anti-prion medication.
Sources: en.wikipedia.org
=== Mechanism === Younes and Loveland define fission as, "...a collective motion of the protons and neutrons that make up the nucleus, and as such it is distinguishable from other phenomena that break up the nucleus. Nuclear fission is an extreme example of large-amplitude collective motion that results in the division of a parent nucleus into two or more fragment nuclei. The fission process can occur spontaneously, or it can be induced by an incident particle." The energy from a fission reaction is produced by its fission products, though a large majority of it, about 85 percent, is found in fragment kinetic energy, while about 6 percent each comes from initial neutrons and gamma rays and those emitted after beta decay, plus about 3 percent from neutrinos as the product of such decay.
=== Skin === Substances that come into contact with the skin, such as latex, are also common causes of allergic reactions, known as contact dermatitis or eczema. Skin allergies frequently cause rashes, or swelling and inflammation within the skin, in what is known as a "wheal and flare" reaction characteristic of hives and angioedema.
Because radon is quite electropositive for a noble gas, it is possible that radon fluorides actually take on highly fluorine-bridged structures and are not volatile. Extrapolation down the noble gas group would suggest also the possible existence of RnO, RnO2, and RnOF4, as well as the first chemically stable noble gas chlorides RnCl2 and RnCl4, but none of these have yet been found. Radon carbonyl (RnCO) has been predicted to be stable and to have a linear molecular geometry. The molecules Rn2 and RnXe were found to be significantly stabilized by spin-orbit coupling. Radon caged inside a fullerene has been proposed as a drug for tumors. Despite the existence of Xe(VIII), no Rn(VIII) compounds have been claimed to exist; RnF8 should be highly unstable chemically (XeF8 is thermodynamically unstable). Radon reacts with the liquid halogen fluorides ClF, ClF3, ClF5, BrF3, BrF5, and IF7 to form RnF2. In halogen fluoride solution, radon is nonvolatile and exists as the RnF+ and Rn2+ cations; addition of fluoride anions results in the formation of the complexes RnF3− and RnF42−, paralleling the chemistry of beryllium(II) and aluminium(III). The standard electrode potential of the Rn2+/Rn couple has been estimated as +2.0 V, although there is no evidence for the formation of stable radon ions or compounds in aqueous solution.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.